U.S. markets closed
  • S&P 500

    +51.87 (+1.60%)
  • Dow 30

    +358.56 (+1.34%)
  • Nasdaq

    +241.26 (+2.26%)
  • Russell 2000

    +23.09 (+1.59%)
  • Crude Oil

    -0.27 (-0.67%)
  • Gold

    -12.60 (-0.67%)
  • Silver

    -0.21 (-0.91%)

    -0.0038 (-0.33%)
  • 10-Yr Bond

    -0.0070 (-1.05%)

    -0.0008 (-0.06%)

    +0.0980 (+0.09%)

    +55.66 (+0.52%)
  • CMC Crypto 200

    +12.36 (+5.67%)
  • FTSE 100

    +19.89 (+0.34%)
  • Nikkei 225

    +116.82 (+0.51%)

AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates

Zacks Equity Research

AngioDynamics Inc. ANGO reported second-quarter fiscal 2020 adjusted earnings per share (EPS) of 6 cents, which beat the Zacks Consensus Estimate of 2 cents. However, the bottom line dropped a significant 52.9% from the year-ago quarter.

Revenues of this Zacks Rank #3 (Hold) company totaled $70 million, falling short of the Zacks Consensus Estimate of $71.9 million. The top line however inched up 0.03% on a year-over-year basis. Organically, revenues were flat year over year.

Geographical Analysis

In the quarter under review, U.S. net revenues totaled $55.6 million, down 1.3% year over year and at constant currency (cc).

International revenues summed $14.4 million, up 5.6%. At cc, revenues rose 6.6%.

AngioDynamics, Inc. Price, Consensus and EPS Surprise


AngioDynamics, Inc. Price, Consensus and EPS Surprise
AngioDynamics, Inc. Price, Consensus and EPS Surprise

AngioDynamics, Inc. price-consensus-eps-surprise-chart | AngioDynamics, Inc. Quote

Segmental Analysis

Vascular Interventions and Therapies (VIT) Business

VIT revenues in the second quarter grossed $31.2 million, up 0.6% from the year-ago quarter’s figure.

Per management, strong growth in AngioVac and core VIT product line drove revenues.

Vascular Access (VA) Business

Revenues at this segment amounted to $22.8 million, down 4% on a year-over-year basis. Per management, lower sales of Ports and PICCs impeded quarterly growth.

Oncology/Surgery Business

Revenues at the Oncology segment improved 5.1% year over year to $16.1 million. Per management, higher sales of NanoKnife and the Alatus and IsoLoc balloon products drove the upside.

Margin Analysis

In the quarter under review, gross profit totaled $41.5 million, up 2.4% from the year-ago quarter number. Also, gross margin was 59.3%, up 140 basis points (bps) primarily driven by productivity and supply chain improvement as well as positive product mix.

Research and development expenses were $7.8 million, up 9.7% year over year. Sales and marketing expenses totaled $19.4 million, up 4.4% on a year-over-year basis. General and administrative expenses were $11 million, up 18.7%.

Guidance Reiterated

For fiscal 2020, AngioDynamics continues to expect revenues in the $280-$286 million band. The Zacks Consensus Estimate is pegged at $281.4 million, within the projected range.

The company expects EPS within 10-15 cents. The Zacks Consensus Estimate is pinned at $12 cents, much above the guided range.

Gross margin is projected in the range of 58-59%.

Notably, AngioDynamics anticipates investments related to the product launches acquired from Eximo in the second half of fiscal 2020.


AngioDynamics exited the fiscal second quarter on a mixed note. However, the company is consistently gaining from its core Oncology and VIT business units, which witnessed solid growth backed by impressive performance of the Fluid Management and AngioVac units. Management is optimistic about the recent acquisition of the C3 Wave PICC tip location system from Medical Components Inc. Apart from these, the company has completed the sale of NAMIC Fluid Management business to Medline Industries in recent times. The company has kept its fiscal 2020 view intact.

Nonetheless, softness in the company’s Vascular Access business and dismal show by the Ports and PICCs product lines raise concerns. Also, the bottom line saw a significant downside in the quarter.

Key Picks

Some better-ranked stocks in the broader medical space are Cerner Corporation CERN, DexCom DXCM and HealthEquity HQY. While HealthEquity sports a Zacks Rank #1 (Strong Buy), Cerner and DexCom carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Cerner’s fourth-quarter revenues is pegged at $1.43 billion, suggesting a year-over-year increase of 5%. The same for EPS stands at 74 cents indicating a year-over-year upside of 17.5%.

The Zacks Consensus Estimate for DexCom’s fourth-quarter revenues is pinned at $427.5 million, calling for a year-over-year increase of 26.5%. The same for EPS stands at 71 cents, hinting at year-over-year growth of 31.5%.

The Zacks Consensus Estimate for HealthEquity’s fiscal fourth-quarter revenues is pegged at $193.3 million, calling for year-over-year increase of 155%. The same for EPS stands at 18 cents.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cerner Corporation (CERN) : Free Stock Analysis Report
AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
HealthEquity, Inc. (HQY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research